Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates [Yahoo! Finance]
Spruce Biosciences, Inc. (SPRB)
Company Research
Source: Yahoo! Finance
Following Positive Type B Meetings with the FDA, BLA Submission for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) on Track for the Fourth Quarter of 2026 Appoints Dale Hooks as Chief Commercial Officer, Strengthening the Company's Commercial Capabilities in Preparation for a Potential Launch of TA-ERT Secured up to $50 Million in Growth Capital from Avenue Capital Group SOUTH SAN FRANCISCO, Calif., March 09, 2026 BUSINESS WIRE Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2025 and provided corporate updates. "2025 was a very productive year, and our team continues to execute and drive towards key milestones with our tralesinidase alfa enzyme replacement therapy (TA-ERT) program, especially our planned biologics license application (BLA) su
Show less
Read more
Impact Snapshot
Event Time:
SPRB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SPRB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SPRB alerts
High impacting Spruce Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
SPRB
News
- Does Spruce Biosciences (SPRB) Have the Potential to Rally 208.32% as Wall Street Analysts Expect? [Yahoo! Finance]Yahoo! Finance
- Spruce Biosciences (SPRB) Appoints Dale Hooks as CCO and Reports Narrowed $39M 2025 Net Loss [Yahoo! Finance]Yahoo! Finance
- Spruce Biosciences (SPRB) had its price target lowered by Citizens Jmp from $180.00 to $170.00. They now have a "market outperform" rating on the stock.MarketBeat
- Spruce Biosciences (SPRB) had its "buy" rating reaffirmed by HC Wainwright. They now have a $200.00 price target on the stock.MarketBeat
- Spruce Biosciences GAAP EPS of -$50.83 misses by $29.59 [Seeking Alpha]Seeking Alpha
SPRB
Sec Filings
- 3/9/26 - Form 4
- 3/9/26 - Form 3
- 3/9/26 - Form 424B5
- SPRB's page on the SEC website